LLY250110P820000
- 40.00
- 0.000.00%
Eli Lilly and Co Newsroom
Medicare Expands Coverage of Eli Lilly's Weight-Loss Drug -- WSJ
Express News | Eli Lilly - New Centre Expected to Open in Mid-2025
Express News | Lilly - to Establish New Global Capability Centre in Hyderabad, India
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Express News | CMS: With FDA Approved Use for Zepbound to Treat Obstructive Sleep Apnea, Current Medicare Part D and Medicaid Coverage Rules Apply
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Novo Nordisk Needs Answers to These 5 Key Questions
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146
Express News | Remedium Lifecare - Calls Media Reports Claiming Co Got Order From Eli Lilly Speculative, Unfounded
Lilly to Participate in J.P. Morgan Healthcare Conference